Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation

RJ Mead, N Shan, HJ Reiser, F Marshall… - Nature Reviews Drug …, 2023 - nature.com
Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of
motor neurons. As with all major neurodegenerative disorders, development of disease …

[HTML][HTML] The role of mitochondria in amyotrophic lateral sclerosis

EF Smith, PJ Shaw, KJ De Vos - Neuroscience letters, 2019 - Elsevier
Mitochondria are unique organelles that are essential for a variety of cellular processes
including energy metabolism, calcium homeostasis, lipid biosynthesis, and apoptosis …

ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?

D Petrov, C Mansfield, A Moussy… - Frontiers in aging …, 2017 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of
30,000 patients a year worldwide. The median reported survival time since onset ranges …

Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease

L Ng, F Khan, CA Young… - Cochrane Database of …, 2017 - cochranelibrary.com
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease - Ng, L - 2017 |
Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …

The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future

HJ Wobst, KL Mack, DG Brown… - Medicinal research …, 2020 - Wiley Online Library
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …

Interventions for fatigue and weight loss in adults with advanced progressive illness

C Payne, PJ Wiffen, S Martin - Cochrane Database of …, 2012 - cochranelibrary.com
Background Fatigue and unintentional weight loss are two of the commonest symptoms
experienced by people with advanced progressive illness. Appropriate interventions may …

Glial cells—The strategic targets in amyotrophic lateral sclerosis treatment

T Filipi, Z Hermanova, J Tureckova, O Vanatko… - Journal of clinical …, 2020 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by
the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently …

SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments

PI Joyce, P Fratta, EMC Fisher… - Mammalian Genome, 2011 - Springer
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with no cure.
Breakthroughs in understanding ALS pathogenesis came with the discovery of dominant …

Creatine for neuroprotection in neurodegenerative disease: end of story?

A Bender, T Klopstock - Amino Acids, 2016 - Springer
Creatine (Cr) is a natural compound that plays an important role in cellular energy
homeostasis. In addition, it ameliorates oxidative stress, glutamatergic excitotoxicity, and …

Electrical impedance myography as a biomarker to assess ALS progression

SB Rutkove, JB Caress, MS Cartwright… - Amyotrophic Lateral …, 2012 - Taylor & Francis
Electrical impedance myography (EIM), a non-invasive, electrophysiological technique, has
preliminarily shown value as an ALS biomarker. Here we perform a multicenter study to …